FTC, Catalent and Novo Holdings
Novo Holdings' $16.5B Catalent buyout in crosshairs as consumer groups ask FTC to block the deal
Novo Holdings is encountering more resistance as it aims to close its $16.5 billion acquisition of pharma manufacturing giant Catalent by the end of the year. | A dozen consumer groups and trade unions penned a letter to Lina Khan,
We recently compiled a list of the 10 Most Promising Biotech Stocks According to Hedge Funds. In this article, we are going ...
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
After hitting a wall with the FDA last year, Novo Nordisk has picked up backing from European drug reviewers for its novel ...
We recently published an article titled, Jim Cramer’s Latest Lightning Round: 12 Stocks to Watch. In this article, we are ...
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...
Novo Nordisk and Viatris have agreed to resolve a patent dispute related to Novo's blockbuster weight-loss drugs Ozempic and ...
Novo Nordisk’s stock declined 12% in the past month. Wegovy's sales growth stays under pressure. Read why I'm neutral on NVO ...
Drugs such as Novo Nordisk’s Ozempic can cut drug and alcohol abuse by up to 50%, a study found, adding to mounting evidence ...
This week marked the start of the third-quarter earnings season, with Johnson & Johnson exceeding Wall Street’s expectations.
Novo Nordisk announced the European Medicines Agency's CHMP has adopted a positive opinion, recommending approval of Alhemo as the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback